(NASDAQ:RLAY) Chief Monetary Officer Thomas Catinazzo offered 17,717 shares of frequent inventory on April 7, 2026, at costs starting from $12.42 to $13.46, for a complete worth of $257,498. The sale comes as shares commerce close to their 52-week excessive of $15, reflecting a exceptional 576% acquire over the previous yr. Based on InvestingPro evaluation, the inventory seems overvalued at present ranges.
Based on a Kind 4 submitting with the Securities and Trade Fee, Catinazzo additionally exercised choices to accumulate 1,800 shares of Relay Therapeutics frequent inventory at a worth of $5.22 on April ninth, 2026. He then offered these shares at $15.00, for a complete of $27,000. The submitting signifies that these transactions have been executed beneath a pre-arranged Rule 10b5-1 buying and selling plan adopted on October 30, 2025.
Following these transactions, Catinazzo instantly owns 213,867 shares of Relay Therapeutics, Inc., together with 13,075 shares underlying restricted inventory models. He additionally instantly owns 61,563 shares of inventory choices. An InvestingPro tip notes the corporate holds additional cash than debt on its steadiness sheet, with detailed evaluation out there within the complete Professional Analysis Report.
In different current information, Relay Therapeutics introduced Part 1/2 trial knowledge for its breast most cancers drug, zovegalisib, mixed with fulvestrant. The trial, which focuses on sufferers with PI3Kα-mutated, HR+/HER2- metastatic breast most cancers, evaluated a 400mg twice-daily dose taken with meals. The info confirmed an 11.1-month progression-free survival, as famous by Oppenheimer, which reiterated an Outperform ranking with a $14 worth goal. H.C. Wainwright additionally raised its worth goal to $19, sustaining a Purchase ranking, following these promising trial outcomes.
Raymond James reiterated a Robust Purchase ranking and a $19 worth goal for Relay Therapeutics, highlighting Novartis’s acquisition of a competing drug candidate. Guggenheim elevated its worth goal to $22, citing the vascular malformations alternative and projecting important gross sales potential for zovegalisib. These developments underscore the optimistic sentiment amongst analysts concerning Relay Therapeutics’ prospects within the oncology area.
This text was generated with the help of AI and reviewed by an editor. For extra data see our T&C.
